Community Research and Development Information Service - CORDIS

Results 1 - 10 of 97
Order by: Results/page:
12 3 4 5 6 7 8 9 10 > 
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases
ID: 115565
Start date: 2014-02-01, End date: 2019-01-31
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such know...
Programme: FP7-JTI
Record Number: 203714
Last updated on: 2017-07-16
Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)
ID: 115439
Start date: 2012-10-01, End date: 2018-03-31
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeuti...
Programme: FP7-JTI
Record Number: 203708
Last updated on: 2017-07-12
Embedded Multi-Core Systems for Mixed Criticality Applications in Dynamic and Changeable Real-Time Environments
ID: 621429
Start date: 2014-04-01, End date: 2017-06-30
Embedded systems are the key innovation driver to improve almost all mechatronic products with cheaper and even new functionalities. Furthermore, they strongly support today's information society as inter-system communication enabler. Consequently boundaries of application do...
Programme: FP7-JTI
Record Number: 185734
Last updated on: 2017-07-02
MOdeling and DEsign of Reliable, process variation-aware Nanoelectronic devices, circuits and systems
ID: 120003
Start date: 2009-03-01, End date: 2012-02-01
The influence of process variations is becoming extremely critical for nanoCMOS technology nodes, due to geometric tolerances and manufacturing non-idealities (such as edge or surface roughness, or the fluctuation of the number of doping atoms). As a result, production yields...
Programme: FP7-JTI
Record Number: 210895
Last updated on: 2017-06-27
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
ID: 115749
Start date: 2015-01-01, End date: 2019-12-31
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary ...
Programme: FP7-JTI
Record Number: 203725
Last updated on: 2017-06-26
Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections
ID: 115737
Start date: 2015-01-01, End date: 2021-12-31
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P....
Programme: FP7-JTI
Record Number: 203724
Last updated on: 2017-06-05
Pharmaceutical Medicine Training Programme
ID: 115013
Start date: 2009-05-01, End date: 2014-04-30
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety...
Programme: FP7-JTI
Record Number: 203685
Last updated on: 2017-05-30
European Modular Education and Training Programme in Safety Sciences for Medicines
ID: 115012
Start date: 2010-01-01, End date: 2016-09-30
Background: In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial ...
Programme: FP7-JTI
Record Number: 203684
Last updated on: 2017-05-30
DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE
ID: 115618
Start date: 2014-10-01, End date: 2017-09-30
Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mecha...
Programme: FP7-JTI
Record Number: 203717
Last updated on: 2017-05-30
The Open Pharmacological Concepts Triple Store
ID: 115191
Start date: 2011-03-01, End date: 2016-02-29
Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, re...
Programme: FP7-JTI
Record Number: 203694
Last updated on: 2017-05-30
12 3 4 5 6 7 8 9 10 > 
List retrieved on: 2017-07-21
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top